Key predictive factors for efficacy of axitinib in first-line metastatic renal cell carcinoma: subgroup analysis in Japanese patients from a randomized, double-blind phase II study.
about
Overall survival of first-line axitinib in metastatic renal cell carcinoma: Japanese subgroup analysis from phase II studyAxitinib in metastatic renal cell carcinoma: beyond the second-line setting.Nivolumab versus everolimus in advanced renal cell carcinoma: Japanese subgroup analysis from the CheckMate 025 study.Pharmacogenetics-based area-under-curve model can predict efficacy and adverse events from axitinib in individual patients with advanced renal cell carcinoma.Hypertension in malignancy-an underappreciated problem.
P2860
Key predictive factors for efficacy of axitinib in first-line metastatic renal cell carcinoma: subgroup analysis in Japanese patients from a randomized, double-blind phase II study.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 29 August 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Key predictive factors for eff ...... , double-blind phase II study.
@en
Key predictive factors for eff ...... , double-blind phase II study.
@nl
type
label
Key predictive factors for eff ...... , double-blind phase II study.
@en
Key predictive factors for eff ...... , double-blind phase II study.
@nl
prefLabel
Key predictive factors for eff ...... , double-blind phase II study.
@en
Key predictive factors for eff ...... , double-blind phase II study.
@nl
P2093
P2860
P356
P1476
Key predictive factors for eff ...... , double-blind phase II study.
@en
P2093
Angel H Bair
Brian I Rini
Hideyuki Akaza
Hirotsugu Uemura
Mototsugu Oya
Nobuo Shinohara
Satoshi Fukasawa
Seiichiro Ozono
Seiji Naito
Tomonori Habuchi
P2860
P356
10.1093/JJCO/HYW103
P577
2016-08-29T00:00:00Z